Experience with Uralyt-U citralite used in patients with gout and nephrolithiasis

Abstract

The paper gives the results of an open-label trial of the Uralyt-U citrate used in 30 patients with gout and nephrolithiasis. In addition to rapid urine pH optimization, the use of the drug is shown to cause a reduction in the serum level of uric acid, correlating with its enhanced excretion. The use of the agent features good compliance and fails to affect renal functional parameters.

Keywords

• gout
• uric acid
• nephrolithiasis
• citrates
• Uralyt-U